Edina Pallagi

992 total citations
28 papers, 708 citations indexed

About

Edina Pallagi is a scholar working on Pharmaceutical Science, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edina Pallagi has authored 28 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmaceutical Science, 9 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edina Pallagi's work include Drug Solubulity and Delivery Systems (10 papers), Advanced Drug Delivery Systems (10 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Edina Pallagi is often cited by papers focused on Drug Solubulity and Delivery Systems (10 papers), Advanced Drug Delivery Systems (10 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Edina Pallagi collaborates with scholars based in Hungary, Pakistan and France. Edina Pallagi's co-authors include Ildikó Csóka, Piroska Szabó‐Révész, Rita Ambrus, Orsolya Jójárt‐Laczkovich, Dorina Gabriella Dobó, Zsófia Németh, Gábor Katona, Zoltán Kónya, Kálmán Tóth and Zoltán Aigner and has published in prestigious journals such as Molecules, International Journal of Pharmaceutics and Acta Neuropathologica.

In The Last Decade

Edina Pallagi

25 papers receiving 697 citations

Peers

Countries citing papers authored by Edina Pallagi

Since Specialization

Citations

This map shows the geographic impact of Edina Pallagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edina Pallagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edina Pallagi more than expected).

Fields of papers citing papers by Edina Pallagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edina Pallagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edina Pallagi. The network helps show where Edina Pallagi may publish in the future.

Co-authorship network of co-authors of Edina Pallagi

This figure shows the co-authorship network connecting the top 25 collaborators of Edina Pallagi. A scholar is included among the top collaborators of Edina Pallagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edina Pallagi. Edina Pallagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development 2021 ·Pharmaceutics ·Zsófia Németh, Edina Pallagi, Dorina Gabriella Dobó, Gábor Kozma, Zoltán Kónya, Ildikó Csóka	21
2	Quality-by-Design-Based Development of n-Propyl-Gallate-Loaded Hyaluronic-Acid-Coated Liposomes for Intranasal Administration 2021 ·Molecules ·Fakhara Sabir, Gábor Katona, Edina Pallagi, Dorina Gabriella Dobó, (unknown), (unknown), Zoltán Kónya, Ildikó Csóka	22
3	Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development 2021 ·Current Medicinal Chemistry ·Ildikó Csóka, (unknown), Orsolya Jójárt‐Laczkovich, Edina Pallagi	52
4	Aerodynamic properties and in silico deposition of isoniazid loaded chitosan/thiolated chitosan and hyaluronic acid hybrid nanoplex DPIs as a potential TB treatment 2020 ·International Journal of Biological Macromolecules ·Mahwash Mukhtar, Edina Pallagi, Ildikó Csóka, (unknown), Árpád Farkas, Mahira Zeeshan, Katalin Burián, (unknown), Rita Ambrus	35
5	Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach 2020 ·Pharmaceutics ·Gábor Katona, György Tibor Balogh, Gergő Dargó, Róbert Gáspár, Árpád Márki, Eszter Ducza, Anita Sztojkov‐Ivanov, (unknown), (unknown), Tamás Janáky, T. Kiss, Rita Ambrus, Edina Pallagi, Piroska Szabó‐Révész, Ildikó Csóka	41
6	Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach 2019 ·European Journal of Pharmaceutical Sciences ·(unknown), Edina Pallagi, Gábor Olajos, Ildikó Csóka	26
7	Application of the QbD-based approach in the early development of liposomes for nasal administration 2019 ·International Journal of Pharmaceutics ·Edina Pallagi, Orsolya Jójárt‐Laczkovich, Zsófia Németh, Piroska Szabó‐Révész, Ildikó Csóka	31
8	Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach 2018 ·European Journal of Pharmaceutical Sciences ·Csilla Bartos, Edina Pallagi, Piroska Szabó‐Révész, Rita Ambrus, Gábor Katona, T. Kiss, (unknown), Ildikó Csóka	21
9	Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes 2018 ·Drug Discovery Today ·Ildikó Csóka, Edina Pallagi, (unknown)	32
10	Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development 2018 ·European Journal of Pharmaceutical Sciences ·Edina Pallagi, Ruba Ismail, (unknown), Ildikó Csóka	34
11	Preliminary study of nanonized lamotrigine containing products for nasal powder formulation 2017 ·Drug Design Development and Therapy ·(unknown), Ildikó Csóka, Edina Pallagi, Gábor Katona, Orsolya Jójárt‐Laczkovich, Piroska Szabó‐Révész, Rita Ambrus	20
12	Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach 2016 ·Drug Design Development and Therapy ·(unknown), Edina Pallagi, Piroska Szabó‐Révész, Ildikó Csóka, Rita Ambrus	48
13	New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach 2016 ·International Journal of Pharmaceutics ·Edina Pallagi, (unknown), Rita Ambrus, Piroska Szabó‐Révész, Ildikó Csóka	36
14	Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation 2015 ·International Journal of Pharmaceutics ·Edina Pallagi, Rita Ambrus, Piroska Szabó‐Révész, Ildikó Csóka	85
15	New thermogravimetric protocol for the investigation of normal and damaged human hyaline cartilage 2007 ·Journal of Thermal Analysis and Calorimetry ·(unknown), Edina Pallagi, Piroska Szabó‐Révész, Kálmán Tóth	28
16	370 COMPLEX THERMAL PROPERTIES OF HUMAN CARTILAGE IN GRADE 4 OSTEOARTHRITIS 2007 ·Osteoarthritis and Cartilage ·(unknown), Z. Aigner, Edina Pallagi, Piroska Szabó‐Révész, Kálmán Tóth	0
17	Development of spherical iron(II) sulfate heptahydrate-containing solid particles with sustained drug release 2006 ·European Journal of Pharmaceutics and Biopharmaceutics ·Piroska Szabó‐Révész, (unknown), (unknown), (unknown), Edina Pallagi	3
18	Study of thermal behaviour of sugar esters 2006 ·International Journal of Pharmaceutics ·(unknown), Edina Pallagi, Géza Regdon, Zoltán Aigner, Piroska Szabó‐Révész	47
19	Iron(II) sulfate release from drop-formed lipophilic matrices developed by special hot-melt technology 2004 ·European Journal of Pharmaceutics and Biopharmaceutics ·Edina Pallagi, Keith Vass, Klára Pintye‐Hódi, P. Kása, G. Falkay, I Erös, Piroska Szabó‐Révész	7
20	Central core and nemaline rods in the same patient 1998 ·Acta Neuropathologica ·Edina Pallagi, Mária Judit Molnár, Péter Molnár, Péter Diószeghy	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact